- Home
- CX vs ROIV Comparison
CX vs ROIV Comparison
Compare CX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CX
- ROIV
- Stock Information
- Founded
- CX 1906
- ROIV 2014
- Country
- CX Mexico
- ROIV United Kingdom
- Employees
- CX N/A
- ROIV N/A
- Industry
- CX Building Materials
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CX Industrials
- ROIV Health Care
- Exchange
- CX Nasdaq
- ROIV Nasdaq
- Market Cap
- CX 8.6B
- ROIV 7.8B
- IPO Year
- CX 1999
- ROIV N/A
- Fundamental
- Price
- CX $7.24
- ROIV $10.99
- Analyst Decision
- CX Buy
- ROIV Buy
- Analyst Count
- CX 5
- ROIV 4
- Target Price
- CX $7.45
- ROIV $17.50
- AVG Volume (30 Days)
- CX 12.1M
- ROIV 7.2M
- Earning Date
- CX 07-24-2025
- ROIV 08-07-2025
- Dividend Yield
- CX 1.17%
- ROIV N/A
- EPS Growth
- CX 591.00
- ROIV N/A
- EPS
- CX 0.10
- ROIV N/A
- Revenue
- CX $15,906,684,000.00
- ROIV $29,053,000.00
- Revenue This Year
- CX $3.44
- ROIV $2.64
- Revenue Next Year
- CX $3.26
- ROIV $378.09
- P/E Ratio
- CX $7.68
- ROIV N/A
- Revenue Growth
- CX N/A
- ROIV N/A
- 52 Week Low
- CX $4.89
- ROIV $8.73
- 52 Week High
- CX $7.34
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CX 65.70
- ROIV 44.89
- Support Level
- CX $6.67
- ROIV $10.83
- Resistance Level
- CX $7.27
- ROIV $11.82
- Average True Range (ATR)
- CX 0.17
- ROIV 0.32
- MACD
- CX 0.02
- ROIV -0.07
- Stochastic Oscillator
- CX 95.31
- ROIV 16.75
About CX Cemex S.A.B. de C.V. Sponsored ADR
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.